Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 nov. 2024 07h30 HE | Source: Angitia Incorporated Limited

Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis

WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
26 mars 2024 08h30 HE | Source: Entera Bio Ltd.

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American...
02 nov. 2023 08h00 HE | Source: Ractigen Therapeutics

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
10 nov. 2022 16h15 HE | Source: Entera Bio Ltd.

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
21 sept. 2022 08h30 HE | Source: Entera Bio Ltd.

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET

JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today...
18 juil. 2022 07h05 HE | Source: Entera Bio Ltd.

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the...
03 juin 2022 17h00 HE | Source: Univest Securities, LLC

Univest Securities, LLC Announces Closing of $25 Million IPO for its Client Zhong Yang Financial Group Limited (Nasdaq: TOP)

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York,...
31 janv. 2019 09h00 HE | Source: TAMKO Building Products, Inc.

BMD Adds TAMKO’s Envision Decking in Southern California

JOPLIN, MISSOURI, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Building Materials Distributors, Inc. (BMD) is now distributing TAMKO Building Products, Inc.’s Envision® composite decking in southern...